Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $124

Benzinga · 2d ago
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $119 to $124.